Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Dr. Steven Gray

Clinical Senior Lecturer (Clinical Medicine)


Clinical Senior Lecturer (Molecular Medicine Ireland)

Steven Gray graduated from Trinity College Dublin in 1992. He joined the laboratory of Tomas J. Ekstrom at the Karolinska Institute in 1996 and received his PhD in 2000 (Thesis Title: The IGF-axis in liver disease: Modulation of expression by histone deacetylase inhibitors). He moved to the Van Andel Research Institute in Michigan, USA where he continued his studies on the therapeutic potential of histone deacetylase inhibitors in the treatment of cancer. He also spent some time as a visting fellow at Harvard Medical School, Boston working on epigenetic therapies for neurodegenerative disease. Returning to Europe Dr Gray spent some time at the German Cancer Research Centre (DKFZ - Heidelberg), and subsequently moved to Copenhagen to work for Novo Nordisk as part of the research team of Prof Pierre De Meyts at the Hagedorn Research Institute working on epigenetic mechanisms underpinning diabetes pathogenesis. Dr Gray is currently a senior clinical scientist at St James's Hospital in the Deprtment of Clinical Oncology at the Thoraacic Oncology Research Group at St. James's Hospital headed by Dr. Sinead Cuffe and Professor Stephen Finn, and holds an adjunct assistant professorship with the Dept of Clinical Medicine (TCD).
Details Date
Steering Committee Mesothelioma Research Network Steering Group (UK) (2018 - 2022) 2018-2022
Senior Board Member BMC Pulmonary Medicine 2020-present
Section Editor: Clinical Epigenetics ( 2018-present
Associate Editor Molecular and Structural Endocrinology (specialty section of Frontiers in Endocrinology) 2018-present
Associate Editor: BMC Cancer 2019-present
Associate Editor: PLoS One 2018-present
Editorial Board: International Journal of Oncology 2016-present
Editorial Board: Cancers (MDPI) 2017-present
Editorial Board: Cells (MDPI) 2019-present
Grant reviewer Australian National Health and Medical Research Council (NHMRC) (2010, 2012, 2017) Austrian Science Fund (2011, 2019) Bulgarian Science Foundation (2008) British Lung Foundation (2010, 2020) Cancer Research UK (2009) Czech Science Foundation (2012) Cyprus Research Promotion Foundation (2011) The Dutch Organisation for Health Research and Development (ZonMw) (2017) The Eli and Edythe Broad Foundation - Broad Medical Research Program (2012) Enterprise Ireland Commercialisation Fund (2005, 2006, 2008) Eureka Eurostars Technical Experts (2015-2020) EU - H2020-Marie Skłodowska-Curie Actions (Reviewer -2020, 2021 ; Rapporteur, 2021) Fondation contre le Cancer - Belgium (2016) Fondazione Pisa - Italy (2016) Fondazione Regionale Per La Ricerca Biomedica [Lomardy Region] (2020, 2022) France's National Research Agency -ANR [Agence Nationale de la Recherche] (2008, 2011) German Research Foundation (2009) 2009-2022
Grant Reviewer (2): German-Israeli Foundation (2011) HRB Medical Charities Research Group (2008) IASLC (2011, 2012, 2013 on behalf of Professor Kenneth J. O'Byrne) INNOVATION FUND DENMARK (2015). Italian Telethon Foundation (2008) Multiple Sclerosis Society (UK) (2012) MRC Medical Research Council (2020) The Netherlands Organisation for Scientific Research (NWO) - VENI program (2013) National Science Centre Poland (OPUS) (2015, 2017) OeNB Anniversary Fund (Austria) (2014, 2015) OTKA - Hungarian Scientific Research Fund (2014, 2015) Prostate Cancer UK (2014) Prostate Cancer Research Centre (2019) Wellcome Trust (2009) Worldwide Cancer Research (2021) Swiss Cancer League (2010, 2018) 2004-2022
Ad Hoc Journal Reviewer for the following: Acta Neuropathologica, Aging, Antioxidants & Redox Signaling, BBA-Reviews on Cancer, BBA - Gene Regulatory Mechanisms, BioEssays, BMC Medical Genetics, BMC Urology, British Journal of Cancer, British Journal of Clinical Pharmacology, British Journal of Pharmacology, Cancer, Cancers (MDPI),Cancer Epidemiology, Cancer Immunology Research, Cancer Letters, Cancer Research, Clinical and Experimental Rheumatology, Cell Biochemistry and Biophysics, Cellular & Molecular Life Sciences, CNS & Neurological Disorders-Drug Targets (CNSND-DT), Clinical Cancer Research, Clinical Lung Cancer, Cytokine, Diabetologia, E-Biomedicine, Epigenetics, European Journal of Cell Biology, European Journal of Pharmacology, Experimental Cell Research, Expert Opinion On Investigational Drugs, Expert Opinion on Therapeutic Targets
Ad hoc reviewer for various journals (2): Future Oncology - Epigenomics, Frontiers in Systems Biology, Genes & Cancer, Genome Medicine, Hormone & Metabolic Research, Inflammation & Allergy - Drug Targets, International Journal of Cancer, International Journal of Immunogenetics, Irish Journal of Medical Science, Journal of Cellular & Molecular Medicine, Journal of Experimental and Molecular Pathology, Journal of Hematology & Oncology, The Journal of Pathology, Journal of Nucleic Acids, Journal of Thoracic Oncology, Life Sciences, Lung Cancer, Mini-Reviews in Medicinal Chemistry, Molecular Cancer Research, Molecular and Cancer Therapeutics, Molecular Therapy
Ad Hoc reviewer for the following journals (3): Neurogenetics, Neurological Research, Neuropsychiatric Disease and Treatment, the Open Diabetes Journal, Oncology Reports, OncoTarget, PLoS One, Pharmaceutical Patent Analyst, Pharmacological Research, Pharmacogenomics, Phytotherapy Research, Progress in Lipid Research, Stem Cells, Theranostics, Translational Research, Trends in Neurosciences, Trends in Molecular Medicine
Panel Member: The International Cancer Genome Consortium (workgroup: Renal Cancer) 2008-2010
Deputy Editor for the Epigenetic Regulators section of the Targeted Proteins database and Epigenetic Regulators section of the CBD Protein Systems journal (launched 2008) 2008 - present
Editorial Board Member The Open Diabetes Journal (Bentham from 2008 2008-2014
Founding Editorial Board Member "Clinical Epigenetics" 2009-present
Member of the Editorial Academy for the "International Journal of Oncology" 2016-present
Editorial Board member "World Journal of Experimental Medicine" (2011-2019) 2011-2019
Editorial Board member "Frontiers in Epigenomics" (Guest Associate Editor & Review Editor)
Editorial Board Member "Frontiers in Systems Physiology" (Review Editor, Systems Biology)
Panel Member: The International Cancer Genome Consortium (workgroup: Renal Cancer) 2008 to present
Editorial Board member World Journal of Biological Chemistry Dec 2013
Invited "ad hoc" contributor to Trends in Genetics Short In Brief Articles section (2001-2002)
Independent Reporter for GenomeBiology ( (2001)
Details Date From Date To
British Thoracic Oncology Group 2005 present
iMiG (International Mesothelioma Interest Group)
ETOP (European Thoracic Oncology Program) -
ToPCaP (Transdisciplinary Prostate Cancer Partnership) -
Perryman L, Gray SG., Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. , Cancers, 14, (4), 2022, p981 , Journal Article, PUBLISHED  DOI
Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, Mutti L., Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma., JAMA Netw Open, 5, (3), 2022, pe221490 , Journal Article, PUBLISHED  DOI
Sui JSY, Finn SP, Gray SG., Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach., Methods in molecular biology (Clifton, N.J.), 2279, 2021, p145-155 , Journal Article, PUBLISHED  DOI
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP., Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids., Journal of nanobiotechnology, 19, (71), 2021, p1-20 , Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
John Greene, Anne-Marie Baird, Marvin Lim, Joshua Flynn, Ciara McNevin, Lauren Brady, Orla Sheils, Steven G Gray, Raymond McDermott, Stephen P Finn, Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer, Frontiers in cell and developmental biology, 9, 2021, p334-, Notes: [], Journal Article, PUBLISHED
Gray SG., Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma., BMC pulmonary medicine, 21, (1), 2021, p148 , Journal Article, PUBLISHED  DOI
MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Gray SG, Reidy M, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP., MicroRNA expression profiling and biomarker validation in treatment-na├»ve and drug resistant non-small cell lung cancer., Translational lung cancer research, 10, (4), 2021, p1773-1791 , Journal Article, PUBLISHED  DOI
Porta C, Nardone V, Gray SG, Correale P, Mutti L., RAMES study: is there really a role for VEGF inhibition in mesothelioma?, The Lancet. Oncology, 22, (12), 2021, pe532 , Journal Article, PUBLISHED  DOI
Lim MCJ, Baird AM, Greene J, McNevin C, Ronan K, Podlesniy P, Sheils O, Gray SG, McDermott RS, Finn SP., hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. , Cancers, 13, (24), 2021, p6383 , Journal Article, PUBLISHED  DOI
Baird AM, Finn SP, Gray SG, Sheils O., Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16, (1), 2021, p14-16 , Journal Article, PUBLISHED  DOI

Page 1 of 13


Award Date
Invited Speaker EFBIC Diabetes Workshop "Shifting paradigms in diabetes" February 26th 2009
My research mainly involves using epigenetic targeting agents to examine fundamental mechanisms underpinning the regulation of (i) Receptor Tyrosine Kinases (RTKs); (ii) inflammation and (iii) cellular metabolism in thoracic malignancy and to study their potential therapeutic efficacy in the treatment of lung cancer and mesothelioma. Research in my laboratory also tries to understand the role of epigenetics and epigenetic mechanisms underpinning drug resistance in lung cancer and mesothelioma. In addition to the above my research also involves the study of non-coding RNA repertoires (lncRNAs and circRNAs) in lung cancer and mesothelioma for their potential utility as candidate biomarkers for the early prediction of thoracic malignancy, and to study their roles in lung cancer biogenesis and resistance to therapy.